JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 ...

Actinium Pharmaceuticals (ATNM) has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center to expand ...

Gene mutations in acute myeloid leukemia (AML) cells can guide treatment options, and machine learning can rapidly guess the ...

TuHURA plans to advance its VISTA inhibiting antibody into a phase two trial in combination with a menin inhibitor in NPM1 mutated relapsed or refractory AML. Leveraging its discovery of the ...

Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A ...

The company’s KOMET-001 pivotal Phase 2 trial in relapsed/refractory NPM1-mutated AML has met its primary endpoint, with detailed results expected to be presented at a medical conference in the second ...

The company’s KOMET-001 pivotal Phase 2 trial in relapsed/refractory NPM1-mutated AML has met its primary endpoint, with detailed results expected to be presented at a medical conference in the ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q4 2024 Earnings Call Transcript March 3, 2025 Operator: Good day, everyone, and welcome to the Syndax Fourth Quarter and Full Year 2024 Earnings ...

We are preparing to file a supplemental new drug application or sNDA next quarter that could expand the indicated population for Revuforj into mutant NPM1 AML around the end of the year.

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML, which serves as a first step to providing ...

We're preparing to commercialize ziftomenib as a potentially best-in-class menin inhibitor for patients with relapsed and/or refractory NPM1-mutant AML, which serves as a first step to providing ...